The evidence is limited. The CMAJ commentary reports a 2021 systematic review of 26 studies with 2,678 participants. Twenty-three of the studies were case series with low-quality evidence, and three randomised trials with 179 patients found no significant difference from vaginal hormone therapy. A high-quality sham-controlled trial of 85 women using a CO2 laser found no significant improvement in symptoms, quality of life or sexual function at 12 months.
For urinary leakage, a sham-controlled trial of 101 women found no improvement. The commentary says pelvic floor therapy or surgery has stronger trial support for that problem.
The commentary also notes an FDA report that burns, scarring, pain during sex and recurring or long-lasting pain can occur with energy-based devices marketed for vaginal rejuvenation. In the trials it describes, no serious side effects were found compared with sham or standard care.